GENT — Gentian Diagnostics ASA Income Statement
0.000.00%
Last trade - 00:00
- NOK706.34m
- NOK629.62m
- NOK135.15m
- 72
- 10
- 65
- 45
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 48 | 63.3 | 83.1 | 102 | 135 |
Cost of Revenue | |||||
Gross Profit | 22.5 | 30.7 | 39.9 | 29 | 56.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 89.2 | 81.2 | 106 | 125 | 148 |
Operating Profit | -41.2 | -17.8 | -22.8 | -23.2 | -12.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -39.8 | -17.5 | -24.8 | -23.6 | -10.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -39.9 | -17.5 | -24.8 | -23.6 | -10.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -39.9 | -17.5 | -24.8 | -23.6 | -10.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -39.9 | -17.5 | -24.8 | -23.6 | -10.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.99 | -1.13 | -1.61 | -1.53 | -0.455 |
Dividends per Share |